Ultragenyx Pharmaceutical Inc. (RARE) Income Statement

The sequence of growth rates indicates that revenue is driven by irregular collaboration and milestone items as much as by steady product demand, which makes any single quarter a poor proxy for trend. The 2026Q2 spike to 28.5% growth followed by a sharp sequential decline in 2026Q3 is consistent with timing-sensitive partner recognition rather than an accelerating commercial base. Investors should monitor whether product-level sales of Crysvita and the owned therapies grow steadily over several consecutive quarters before inferring a sustained growth trajectory.

The gross margin profile is consistent with orphan-drug pricing, where low unit volumes are offset by high per-patient reimbursement, and it compares favorably with peers such as BioMarin at 77.1% and Ionis at 98.3%. However, operating expenses dominated by R&D, which ran at $154M to $216M per quarter, absorb far more than the gross profit generated. This suggests margin improvement depends on either commercial scaling of current products or the transition of pipeline assets out of the development stage.

Because SG&A has been comparatively stable, the operating loss variability is driven mainly by R&D spend and revenue timing rather than by overhead efficiency. The lack of a clear trend toward narrower operating losses even in higher-revenue quarters such as 2026Q2 suggests that incremental revenue is being reinvested rather than falling through. Investors should watch whether R&D intensity declines as a share of revenue, since that is the variable most capable of producing genuine operating leverage.